AIMS: In patients with acute coronary syndromes (ACS), the negative impact of baseline haemoglobin levels on ischaemic events, particularly death, is well established, but the association with bleeding risk is less well studied. The aim of this study was to assess the impact of baseline haemoglobin levels on major bleeding complications. METHODS AND RESULTS: Pooled analysis of OASIS 5 and 6 data involving 32 170 patients with ACS with and without ST-segment elevation was performed. The association between baseline haemoglobin and major bleeding or ischaemic events was examined using multiple regression model. MAIN OUTCOME MEASURES: were 30-day rates of major bleeding, death, and death/myocardial infarction (MI) analysed according to baseline haemoglobin levels. Baseline haemoglobin level independently predicted the risk of overall, procedure-related, and non-procedure-related major bleedings at 30 days [odds ratio (OR) 0.94, 95% CI 0.90-0.98; OR 0.94, 95% CI 0.90-0.99; and OR 0.89, 95% CI 0.83-0.95, respectively, per 1 g/dL haemoglobin increment above 10 g/dL]. In addition, a curvilinear relationship between baseline haemoglobin levels and death at 30 days was observed with a 6% decrease in the risk for every 1 g/dL haemoglobin increment above 10 g/dL up to 15.9 g/dL (OR 0.94, 95% CI 0.90-0.98) and a 19% increase above this value (OR 1.19, 95% CI, 0.98-1.43). A similar relationship for the composite outcome of death/MI was observed. CONCLUSION: A low baseline haemoglobin level is an independent predictor of the risk of major bleeding in ACS as well as of the risk of death and death and MI. Among other predictors of bleeding risk, baseline haemoglobin should be taken into account in patients presenting with ACS. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number, NCT00139815. http://clinicaltrials.gov/ct2/show/NCT00139815?term=NCT00139815&rank=1.
RCT Entities:
AIMS: In patients with acute coronary syndromes (ACS), the negative impact of baseline haemoglobin levels on ischaemic events, particularly death, is well established, but the association with bleeding risk is less well studied. The aim of this study was to assess the impact of baseline haemoglobin levels on major bleeding complications. METHODS AND RESULTS: Pooled analysis of OASIS 5 and 6 data involving 32 170 patients with ACS with and without ST-segment elevation was performed. The association between baseline haemoglobin and major bleeding or ischaemic events was examined using multiple regression model. MAIN OUTCOME MEASURES: were 30-day rates of major bleeding, death, and death/myocardial infarction (MI) analysed according to baseline haemoglobin levels. Baseline haemoglobin level independently predicted the risk of overall, procedure-related, and non-procedure-related major bleedings at 30 days [odds ratio (OR) 0.94, 95% CI 0.90-0.98; OR 0.94, 95% CI 0.90-0.99; and OR 0.89, 95% CI 0.83-0.95, respectively, per 1 g/dL haemoglobin increment above 10 g/dL]. In addition, a curvilinear relationship between baseline haemoglobin levels and death at 30 days was observed with a 6% decrease in the risk for every 1 g/dL haemoglobin increment above 10 g/dL up to 15.9 g/dL (OR 0.94, 95% CI 0.90-0.98) and a 19% increase above this value (OR 1.19, 95% CI, 0.98-1.43). A similar relationship for the composite outcome of death/MI was observed. CONCLUSION: A low baseline haemoglobin level is an independent predictor of the risk of major bleeding in ACS as well as of the risk of death and death and MI. Among other predictors of bleeding risk, baseline haemoglobin should be taken into account in patients presenting with ACS. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number, NCT00139815. http://clinicaltrials.gov/ct2/show/NCT00139815?term=NCT00139815&rank=1.
Authors: Kadhim Sulaiman; Panduranga Prashanth; Ibrahim Al-Zakwani; Wael Al-Mahmeed; Ahmed Al-Motarreb; Jassim Al Suwaidi; Haitham Amin; Nidal Asaad; Ahmad Hersi; Hussam Al Faleh; Shukri Al Saif; Alawi A Alsheikh-Ali; Jawad Al Lawati; Khalid Al-Habib Journal: Clin Med Res Date: 2012-05
Authors: Sylvestre Maréchaux; Stéphanie Barrailler; Claire Pinçon; Vincent Decourcelle; Thomas Guidez; Sophie Braun; Nadia Bouabdallaoui; Jean-Jacques Bauchart; Jean Luc Auffray; Francis Juthier; Carlo Banfi; Sophie Susen; Brigitte Jude; Philippe Asseman; Eric Van Belle; Pierre Vladimir Ennezat Journal: Heart Vessels Date: 2011-05-12 Impact factor: 2.037
Authors: Ralf Erkens; Tatsiana Suvorava; Christian M Kramer; Lukas D Diederich; Malte Kelm; Miriam M Cortese-Krott Journal: Antioxid Redox Signal Date: 2017-02-16 Impact factor: 8.401
Authors: Viktoria Kuhn; Lukas Diederich; T C Stevenson Keller; Christian M Kramer; Wiebke Lückstädt; Christina Panknin; Tatsiana Suvorava; Brant E Isakson; Malte Kelm; Miriam M Cortese-Krott Journal: Antioxid Redox Signal Date: 2017-01-18 Impact factor: 8.401
Authors: Katharina Hellhammer; Tobias Zeus; Pablo E Verde; Verena Veulemanns; Lisa Kahlstadt; Georg Wolff; Ralf Erkens; Ralf Westenfeld; Eliano P Navarese; Marc W Merx; Tienush Rassaf; Malte Kelm Journal: World J Cardiol Date: 2016-02-26
Authors: Peter K Smith; Lawrence T Goodnough; Jerrold H Levy; Robert S Poston; Mary A Short; Govinda J Weerakkody; Leroy A Lenarz Journal: J Am Coll Cardiol Date: 2012-05-23 Impact factor: 24.094
Authors: Jean-Pierre Bassand; Saverio Virdone; Marc Badoz; Freek W A Verheugt; A John Camm; Frank Cools; Keith A A Fox; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gloria Kayani; Frank Misselwitz; Karen S Pieper; Alexander G G Turpie; Martin van Eickels; Ajay K Kakkar Journal: Blood Adv Date: 2021-02-23